The global human microbiome market size is estimated at USD 246.74 million in 2024, grew to USD 309.17 million in 2025 and is predicted to surpass around USD 2,353.70 million by 2034, expanding at a CAGR of 25.30% between 2024 and 2034. The North America human microbiome market size accounted for USD 98.70 million in 2024 and is anticipated to grow at a fastest CAGR of 25.44% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Human Microbiome Market
5.1. COVID-19 Landscape: Human Microbiome Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Human Microbiome Market, By Product
8.1. Human Microbiome Market, by Product, 2024-2034
8.1.1 Prebiotics
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Probiotics
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Drugs
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Medical Foods
8.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Human Microbiome Market, By Application
9.1. Human Microbiome Market, by Application, 2024-2034
9.1.1. Diagnostics
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Therapeutics
9.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Human Microbiome Market, By Disease Type
10.1. Human Microbiome Market, by Disease Type, 2024-2034
10.1.1. Metabolic
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Infectious
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Endocrine
10.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Human Microbiome Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Disease Type (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Disease Type (2021-2034)
Chapter 12. Company Profiles
12.1. AOBiome
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Yakult Honsha Co.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Metabiomics Corp. (BioSpherex LLC)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Enterome Biosciences SA
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Osel, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Microbiome Therapeutics LLC
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Second Genome
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Rebiotix, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Synthetic Biologics, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Seres Therapeutics
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample